The EU Biotech Act Meets Vision 2030: Bridging the $34 Billion Advanced Therapy Divide

The global advanced therapy market is highly fragmented. While Europe possesses world-class scientific research, complex regulatory bottlenecks have historically choked commercialization'causing the EU to capture a mere 7% of global health biotech venture capital. At the same time, Saudi Arabia is rapidly building state-of-the-art biomanufacturing infrastructure but requires established translational pathways to co-develop and import these breakthrough assets. If therapeutic developers and regional investors fail to align with the massive legislative shifts happening right now, they risk being locked out of the next wave of global innovation. Europe's forthcoming Biotech Act is fundamentally rewriting the rules for clinical trials, biomanufacturing, and market access over the next 5 years. Ignoring this overhaul means missing out on lucrative cross-border partnerships. For ecosystem builders in the MENA region, failing to capitalize on these newly opened European pipelines jeopardizes the National Biotechnology Strategy's goal of contributing $34.6 billion to Saudi Arabia's non-oil GDP by 2040. You need to understand how to turn global policy shifts into regional commercial pipelines. In this keynote session, a leading European legislative and market translation expert will decode the EU Biotech Act and the new network of Centres of Excellence for ATMPs (Advanced Therapy Medicinal Products). You will discover how Europe's sweeping regulatory overhaul creates unprecedented co-development and investment opportunities for the Middle East, so you can align your cross-border strategies, leverage Saudi Arabia's booming infrastructure, and position your organization at the forefront of the global advanced therapy market.